Comparison 2. Efficacy ‐ febuxostat 80 mg/day versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Incidence of gout flares	2	474	Risk Ratio (M‐H, Fixed, 95% CI)	1.32 [0.96, 1.81]
1.1 28 days	1	78	Risk Ratio (M‐H, Fixed, 95% CI)	1.15 [0.67, 2.00]
1.2 8 weeks	1	396	Risk Ratio (M‐H, Fixed, 95% CI)	1.38 [0.94, 2.04]
2 Serum uric acid <6.0 mg/dL at final visit	2	332	Risk Ratio (M‐H, Fixed, 95% CI)	68.86 [13.79, 343.94]
2.1 28 days	1	72	Risk Ratio (M‐H, Fixed, 95% CI)	54.0 [3.42, 852.00]
2.2 28 weeks	1	260	Risk Ratio (M‐H, Fixed, 95% CI)	75.02 [10.65, 528.34]
3 Change in serum uric acid concentration from baseline at final visit	2	332	Mean Difference (IV, Random, 95% CI)	‐4.96 [‐6.23, ‐3.68]
3.1 28 days	1	72	Mean Difference (IV, Random, 95% CI)	‐5.63 [‐6.24, ‐5.03]
3.2 28 weeks	1	260	Mean Difference (IV, Random, 95% CI)	‐4.33 [‐4.65, ‐4.02]